SecBot SecBot
SC 13G/A ·Filed Nov 13, 2026

STOK

Stoke Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed3d 9h ago SEC0000895421-26-000321
Passive stake amendment
Actionable Insight • Neutral

Monitor for any further reductions by Morgan Stanley or other large institutional holders. The drop below 5% removes Morgan Stanley from future 13G filing requirements, reducing transparency into their position changes.

DirectionNeutral
Confidencehigh
Horizondays

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Morgan Stanley filed an amended Schedule 13G disclosing a 4.9% beneficial ownership stake in Stoke Therapeutics as of September 30, 2026, down from above 5% in the prior filing. The filing states Morgan Stanley has ceased to be a beneficial owner of more than 5% of the class, indicating a reduction in its passive stake.

Key Financial Metrics

Stake
4.9%
Investor
Morgan Stanley

Key Facts

  • Morgan Stanley reported beneficial ownership of 3,177,169 shares of Stoke Therapeutics common stock, representing 4.9% of shares outstanding as of September 30, 2026.
  • The filing states Morgan Stanley has ceased to be the beneficial owner of more than 5% of the class of securities.
  • Morgan Stanley Capital Services LLC reported 2,653,126 shares (4.1%) as a wholly-owned subsidiary.
  • The filing is an amendment to Schedule 13G, indicating passive investment intent under Rule 13d-1(b).

Financial Impact

Morgan Stanley reduced its stake from above 5% to 4.9%, a decrease of at least 0.1% of shares outstanding.

ownership_percentage

Risk Factors

  • Morgan Stanley's reduction below 5% could signal reduced institutional confidence, though the decrease is small.
  • No specific reason for the reduction is disclosed in the filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0000895421-26-000321
Exhibit: EXHIBIT_NO.99.2.txt0000895421-26-000321
Document: 0000895421-26-000321-index-headers.html0000895421-26-000321
Document: 0000895421-26-000321-index.html0000895421-26-000321
Document: 0000895421-26-000321.txt0000895421-26-000321

Track record

18 reports on STOK

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +17.49% at T+60 after the Aug 3, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $26.63 Now $26.63 −0.00% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $27.02 Now $26.63 −1.44% settles Feb 12
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $26.84 Now $26.63 −0.78% settles Feb 12
  4. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Viewing Entry $26.12 Now $26.63 +1.95% settles Feb 12
  5. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $26.07 Now $26.63 +2.15% settles Feb 3
  6. Oct 29, 202618d ago 8-K Neutral 5/10 Entry $26.29 Now $26.63 +1.29% settles Jan 28
  7. Oct 21, 202626d ago 144 Bearish 6/10 Entry $25.70 Now $26.63 −3.62% settles Jan 20
  8. Sep 30, 20266w ago SC 13G Neutral 4/10 Entry $26.01 Now $26.63 +2.38% settles Dec 28
  9. Sep 25, 20267w ago 8-K Neutral 2/10 Entry $25.50 Now $26.63 +4.43% settles Dec 22
  10. Aug 18, 202612w ago Insider Cluster Neutral 3/10 Entry $33.03 to $26.20 Now $26.63 −19.38% ▼ −20.68% −19.13% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 7h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026